Biological hypotheses and biomarkers of bipolar disorder

Psychiatry and Clinical Neurosciences

Volumn 71, Issue 2, 2017, Pages 77-103

  Sigitova, Ekaterina ^a   Fišar, Zdeněk ^a   Hroudová, Jana ^a   Cikánková, Tereza ^a   Raboch, Jiří ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

Author keywords

bipolar disorder; hypothesis; mitochondrial dysfunction; neuroinflammation; neuroplasticity

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; FLUOXETINE; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; HALOPERIDOL; LITHIUM; METALLOPROTEINASE; MITOCHONDRIAL DNA; NERVE GROWTH FACTOR; NEUROLEPTIC AGENT; NEUROTROPHIC FACTOR; NEUROTROPHIN; NEUROTROPHIN 3; NEUROTROPHIN 4; OLANZAPINE; QUETIAPINE; RISPERIDONE; SEROTONIN; BIOLOGICAL MARKER; CYTOKINE; SIGNAL PEPTIDE;

AUTOIMMUNE DISEASE; BDNF GENE; BIPOLAR DISORDER; BRAIN REGION; BRAIN SIZE; DISEASE MARKER; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG EFFICACY; DRUG RESPONSE; EPIGENETICS; GENE; GENE MUTATION; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOME-WIDE ASSOCIATION STUDY; HUMAN; IMMUNE RESPONSE; INNATE IMMUNITY; MAJOR DEPRESSION; NERVE CELL PLASTICITY; NERVOUS SYSTEM INFLAMMATION; NEUROIMAGING; NEUROPROTECTION; NEUROTRANSMISSION; NITROSATIVE STRESS; OXIDATIVE STRESS; PATHOGENESIS; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT OUTCOME; BLOOD; METABOLISM; MITOCHONDRION; PHYSIOLOGY;

BIOMARKERS; BIPOLAR DISORDER; CYTOKINES; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MITOCHONDRIA; OXIDATIVE STRESS;

EID: 85008502117     PISSN: 13231316     EISSN: 14401819     Source Type: Journal    
DOI: 10.1111/pcn.12476     Document Type: Review

References (288)

1. Uher R. Gene–environment interactions in severe mental illness. Front. Psychiatry 2014; 5: 48.
2. Berk M, Berk L, Dodd S et al. Stage managing bipolar disorder. Bipolar Disord. 2014; 16: 471–477.
3. Berk M, Kapczinski F, Andreazza AC et al. Pathways underlying neuroprogression in bipolar disorder: Focus on inflammation, oxidative stress and neurotrophic factors. Neurosci. Biobehav. Rev. 2011; 35: 804–817.
4. Anderson G, Maes M. Bipolar disorder: Role of immune-inflammatory cytokines, oxidative and nitrosative stress and tryptophan catabolites. Curr. Psychiatry Rep. 2015; 17: 8.
5. Andreazza AC, Young LT. The neurobiology of bipolar disorder: Identifying targets for specific agents and synergies for combination treatment. Int. J. Neuropsychopharmacol. 2014; 17: 1039–1052.
6. Duong A, Syed B, Scola G. Biomarkers for bipolar disorder: Current insights. Curr. Biomark. Find. 2015; 5: 79–92.
7. Scola G, Andreazza AC. Current state of biomarkers in bipolar disorder. Curr. Psychiatry Rep. 2014; 16: 514.
8. Perry DC, Sturm VE, Peterson MJ et al. Association of traumatic brain injury with subsequent neurological and psychiatric disease: A meta-analysis. J. Neurosurg. 2016; 124: 511–526.
9. Mayberg HS. Modulating dysfunctional limbic–cortical circuits in depression: Towards development of brain-based algorithms for diagnosis and optimised treatment. Br. Med. Bull. 2003; 65: 193–207.
10. Savitz J, Drevets WC. Bipolar and major depressive disorder: Neuroimaging the developmental-degenerative divide. Neurosci. Biobehav. Rev. 2009; 33: 699–771.
11. Licznerski P, Duman RS. Remodeling of axo-spinous synapses in the pathophysiology and treatment of depression. Neuroscience 2013; 251: 33–50.
12. Strakowski SM, DelBello MP, Zimmerman ME et al. Ventricular and periventricular structural volumes in first- versus multiple-episode bipolar disorder. Am. J. Psychiatry 2002; 159: 1841–1847.
13. Moorhead TW, McKirdy J, Sussmann JE et al. Progressive gray matter loss in patients with bipolar disorder. Biol. Psychiatry 2007; 62: 894–900.
14. López-Larson MP, DelBello MP, Zimmerman ME, Schwiers ML, Strakowski SM. Regional prefrontal gray and white matter abnormalities in bipolar disorder. Biol. Psychiatry 2002; 52: 93–100.
15. Kempton MJ, Geddes JR, Ettinger U, Williams SC, Grasby PM. Meta-analysis, database, and meta-regression of 98 structural imaging studies in bipolar disorder. Arch. Gen. Psychiatry 2008; 65: 1017–1032.
16. Bora E, Fornito A, Yücel M, Pantelis C. Voxelwise meta-analysis of gray matter abnormalities in bipolar disorder. Biol. Psychiatry 2010; 67: 1097–1105.
17. Hibar DP, Westlye LT, van Erp TG, Rasmussen J et al. Subcortical volumetric abnormalities in bipolar disorder. Mol. Psychiatry 2016; 21: 1710–1716.
18. Maletic V, Raison C. Integrated neurobiology of bipolar disorder. Front. Psychiatry 2014; 5: 98.
19. Cerullo MA, Adler CM, Delbello MP, Strakowski SM. The functional neuroanatomy of bipolar disorder. Int. Rev. Psychiatry 2009; 21: 314–322.
20. Vargas C, López-Jaramillo C, Vieta E. A systematic literature review of resting state network—functional MRI in bipolar disorder. J. Affect. Disord. 2013; 150: 727–735.
21. Kerner B. Genetics of bipolar disorder. Appl. Clin. Genet. 2014; 7: 33–42.
22. Burmeister M, McInnis MG, Zöllner S. Psychiatric genetics: Progress amid controversy. Nat. Rev. Genet. 2008; 9: 527–540.
23. McGuffin P, Rijsdijk F, Andrew M, Sham P, Katz R, Cardno A. The heritability of bipolar affective disorder and the genetic relationship to unipolar depression. Arch. Gen. Psychiatry 2003; 60: 497–502.
24. Kato T. Molecular genetics of bipolar disorder and depression. Psychiatry Clin. Neurosci. 2007; 61: 3–19.
25. Elder BL, Mosack V. Genetics of depression: An overview of the current science. Issues Ment. Health Nurs. 2011; 32: 192–202.
26. Szczepankiewicz A. Evidence for single nucleotide polymorphisms and their association with bipolar disorder. Neuropsychiatr. Dis. Treat. 2013; 9: 1573–1582.
27. Kato T, Kakiuchi C, Iwamoto K. Comprehensive gene expression analysis in bipolar disorder. Can. J. Psychiatry 2007; 52: 763–771.
28. Seifuddin F, Pirooznia M, Judy JT, Goes FS, Potash JB, Zandi PP. Systematic review of genome-wide gene expression studies of bipolar disorder. BMC Psychiatry 2013; 13: 213.
29. Nurnberger JI, Jr, Koller DL, Jung J et al. Identification of pathways for bipolar disorder: A meta-analysis. JAMA Psychiat. 2014; 71: 657–664.
30. Gatt JM, Burton KL, Williams LM, Schofield PR. Specific and common genes implicated across major mental disorders: A review of meta-analysis studies. J. Psychiatr. Res. 2015; 60: 1–13.
31. Kato T. Whole genome/exome sequencing in mood and psychotic disorders. Psychiatry Clin. Neurosci. 2015; 69: 65–76.
32. Craddock N, Sklar P. Genetics of bipolar disorder. Lancet 2013; 381: 1654–1662.
33. Harrison PJ. Molecular neurobiological clues to the pathogenesis of bipolar disorder. Curr. Opin. Neurobiol. 2016; 36: 1–6.
34. Hou L, Bergen SE, Akula N et al. Genome-wide association study of 40,000 individuals identifies two novel loci associated with bipolar disorder. Hum. Mol. Genet. 2016. doi: 10.1093/hmg/ddw181
35. Fišar Z. Pathophysiology of mood disorders and mechanisms of action of antidepressants and mood stabilizers. In: Van Bockstaele EJ (ed.). Endocannabinoid Regulation of Monoamines in Psychiatric and Neurological Disorders. Springer, New York, 2013; 103–134.
36. Schildkraut JJ. The catecholamine hypothesis of affective disorders: A review of supporting evidence. Am. J. Psychiatry 1965; 122: 509–522.
37. Coppen A. The biochemistry of affective disorders. Br. J. Psychiatry 1967; 113: 1237–1264.
38. Heninger GR, Delgado PL, Charney DS. The revised monoamine theory of depression: A modulatory role for monoamines, based on new findings from monoamine depletion experiments in humans. Pharmacopsychiatry 1996; 29: 2–11.
39. aan het Rot M, Mathew SJ, Charney DS. Neurobiological mechanisms in major depressive disorder. CMAJ: Can. Med. Assoc. J. 2009; 180: 305–313.
40. Hamon M, Blier P. Monoamine neurocircuitry in depression and strategies for new treatments. Prog. Neuropsychopharmacol. Biol. Psychiatry 2013; 45: 54–63.
41. Hillhouse TM, Porter JH. A brief history of the development of antidepressant drugs: From monoamines to glutamate. Exp. Clin. Psychopharmacol. 2015; 23: 1–21.
42. Fišar Z. Drugs related to monoamine oxidase activity. Prog. Neuropsychopharmacol. Biol. Psychiatry 2016; 69: 112–124.
43. Craddock N, Davé S, Greening J. Association studies of bipolar disorder. Bipolar Disord. 2001; 3: 284–298.
44. Serretti A, Mandelli L. The genetics of bipolar disorder: Genome 'hot regions,' genes, new potential candidates and future directions. Mol. Psychiatry 2008; 13: 742–771.
45. Rivera M, Gutiérrez B, Molina E et al. High-activity variants of the uMAOA polymorphism increase the risk for depression in a large primary care sample. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2009; 150: 395–402.
46. Meyer JH, Ginovart N, Boovariwala A et al. Elevated monoamine oxidase a levels in the brain: An explanation for the monoamine imbalance of major depression. Arch. Gen. Psychiatry 2006; 63: 1209–1216.
47. Meyer JH, Wilson AA, Sagrati S et al. Brain monoamine oxidase a binding in major depressive disorder: Relationship to selective serotonin reuptake inhibitor treatment, recovery, and recurrence. Arch. Gen. Psychiatry 2009; 66: 1304–1312.
48. 11C]DASB. Psychopharmacology (Berl) 2011; 213: 555–562.
49. Berk M, Dodd S, Kauer-Sant'anna M et al. Dopamine dysregulation syndrome: Implications for a dopamine hypothesis of bipolar disorder. Acta Psychiatr. Scand. Suppl. 2007; 434: 41–49.
50. Dunlop BW, Nemeroff CB. The role of dopamine in the pathophysiology of depression. Arch. Gen. Psychiatry 2007; 64: 327–337.
51. Anand A, Barkay G, Dzemidzic M et al. Striatal dopamine transporter availability in unmedicated bipolar disorder. Bipolar Disord. 2011; 13: 406–413.
52. Rao JS, Kellom M, Reese EA, Rapoport SI, Kim HW. Dysregulated glutamate and dopamine transporters in postmortem frontal cortex from bipolar and schizophrenic patients. J. Affect. Disord. 2012; 136: 63–71.
53. Cannon DM, Carson RE, Nugent AC et al. Reduced muscarinic type 2 receptor binding in subjects with bipolar disorder. Arch. Gen. Psychiatry 2006; 63: 741–747.
54. 2-receptor binding in vivo and accounts for reduced binding in bipolar disorder. Mol. Psychiatry 2011; 16: 407–418.
55. Lener MS, Niciu MJ, Ballard ED et al. Glutamate and gamma-aminobutyric acid systems in the pathophysiology of major depression and antidepressant response to ketamine. Biol. Psychiatry 2016. doi: 10.1016/j.biopsych.2016.05.005
56. Lan MJ, McLoughlin GA, Griffin JL et al. Metabonomic analysis identifies molecular changes associated with the pathophysiology and drug treatment of bipolar disorder. Mol. Psychiatry 2009; 14: 269–279.
57. Gigante AD, Bond DJ, Lafer B, Lam RW, Young LT, Yatham LN. Brain glutamate levels measured by magnetic resonance spectroscopy in patients with bipolar disorder: A meta-analysis. Bipolar Disord. 2012; 14: 478–487.
58. Sanacora G, Zarate CA, Krystal JH, Manji HK. Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders. Nat. Rev. Drug Discov. 2008; 7: 426–437.
59. Jun C, Choi Y, Lim SM et al. Disturbance of the glutamatergic system in mood disorders. Exp. Neurobiol. 2014; 23: 28–35.
60. Gerhard DM, Wohleb ES, Duman RS. Emerging treatment mechanisms for depression: Focus on glutamate and synaptic plasticity. Drug Discov. Today 2016; 21: 454–464.
61. Machado-Vieira R, Henter ID, Zarate CA, Jr. New targets for rapid antidepressant action. Prog. Neurobiol. 2015. doi: 10.1016/j.pneurobio.2015.12.001
62. Kaplan DR, Miller FD. Neurotrophin signal transduction in the nervous system. Curr. Opin. Neurobiol. 2000; 10: 381–391.
63. Jones DM, Tucker BA, Rahimtula M, Mearow KM. The synergistic effects of NGF and IGF-1 on neurite growth in adult sensory neurons: Convergence on the PI 3-kinase signaling pathway. J. Neurochem. 2003; 86: 1116–1128.
64. Miller FD, Kaplan DR. Signaling mechanisms underlying dendrite formation. Curr. Opin. Neurobiol. 2003; 13: 391–398.
65. Skaper SD. The biology of neurotrophins, signalling pathways, and functional peptide mimetics of neurotrophins and their receptors. CNS Neurol. Disord. Drug Targets 2008; 7: 46–62.
66. Fišar Z, Hroudová J. Intracellular signalling pathways and mood disorders. Folia Biol. (Praha) 2010; 56: 135–148.
67. Jacobs WB, Kaplan DR, Miller FD. The p53 family in nervous system development and disease. J. Neurochem. 2006; 97: 1571–1584.
68. Bronfman FC, Lazo OM, Flores C, Escudero CA. Spatiotemporal intracellular dynamics of neurotrophin and its receptors. Implications for neurotrophin signaling and neuronal function. Handb. Exp. Pharmacol. 2014; 220: 33–65.
69. Einat H, Manji HK. Cellular plasticity cascades: Genes-to-behavior pathways in animal models of bipolar disorder. Biol. Psychiatry 2006; 59: 1160–1171.
70. Scola G, Andreazza AC. The role of neurotrophins in bipolar disorder. Prog. Neuropsychopharmacol. Biol. Psychiatry 2015; 56: 122–128.
71. Kim HW, Rapoport SI, Rao JS. Altered expression of apoptotic factors and synaptic markers in postmortem brain from bipolar disorder patients. Neurobiol. Dis. 2010; 37: 596–603.
72. Fernandes BS, Berk M, Turck CW, Steiner J, Gonçalves CA. Decreased peripheral brain-derived neurotrophic factor levels are a biomarker of disease activity in major psychiatric disorders: A comparative meta-analysis. Mol. Psychiatry 2014; 19: 750–751.
73. Fernandes BS, Gama CS, Ceresér KM et al. Brain-derived neurotrophic factor as a state-marker of mood episodes in bipolar disorders: A systematic review and meta-regression analysis. J. Psychiatr. Res. 2011; 45: 995–1004.
74. Lin PY. State-dependent decrease in levels of brain-derived neurotrophic factor in bipolar disorder: A meta-analytic study. Neurosci. Lett. 2009; 466: 139–143.
75. Fernandes BS, Molendijk ML, Köhler CA et al. Peripheral brain-derived neurotrophic factor (BDNF) as a biomarker in bipolar disorder: A meta-analysis of 52 studies. BMC Med. 2015; 13: 289.
76. Polyakova M, Stuke K, Schuemberg K, Mueller K, Schoenknecht P, Schroeter ML. BDNF as a biomarker for successful treatment of mood disorders: A systematic and quantitative meta-analysis. J. Affect. Disord. 2015; 174: 432–440.
77. Fernandes BS, Gama CS, Kauer-Sant'Anna M, Lobato MI, Belmonte-de-Abreu P, Kapczinski F. Serum brain-derived neurotrophic factor in bipolar and unipolar depression: A potential adjunctive tool for differential diagnosis. J. Psychiatr. Res. 2009; 43: 1200–1204.
78. Grande I, Fries GR, Kunz M, Kapczinski F. The role of BDNF as a mediator of neuroplasticity in bipolar disorder. Psychiatry Invest. 2010; 7: 243–250.
79. Karamustafalioglu N, Genc A, Kalelioglu T et al. Plasma BDNFs level initially and post treatment in acute mania: Comparison between ECT and atypical antipsychotic treatment and healthy controls. J. Psychopharmacol. 2015; 29: 898–902.
80. Tramontina JF, Andreazza AC, Kauer-Sant'anna M et al. Brain-derived neurotrophic factor serum levels before and after treatment for acute mania. Neurosci. Lett. 2009; 452: 111–113.
81. 67 mRNA expression in the hippocampus of individuals with schizophrenia and mood disorders. J. Psychiatry Neurosci. 2011; 36: 195–203.
82. Ray MT, Shannon Weickert C, Webster MJ. Decreased BDNF and TrkB mRNA expression in multiple cortical areas of patients with schizophrenia and mood disorders. Transl. Psychiatry 2014; 4: 389.
83. Hashimoto K. Brain-derived neurotrophic factor as a biomarker for mood disorders: An historical overview and future directions. Psychiatry Clin. Neurosci. 2010; 64: 341–357.
84. Pláteník J, Fišar Z, Buchal R et al. GSK3β, CREB, and BDNF in peripheral blood of patients with Alzheimer's disease and depression. Prog. Neuropsychopharmacol. Biol. Psychiatry 2014; 50: 83–93.
85. Pan W, Banks WA, Fasold MB, Bluth J, Kastin AJ. Transport of brain-derived neurotrophic factor across the blood–brain barrier. Neuropharmacology 1998; 37: 1553–1561.
86. Klein AB, Williamson R, Santini MA et al. Blood BDNF concentrations reflect brain-tissue BDNF levels across species. Int. J. Neuropsychopharmacol. 2011; 14: 347–353.
87. Schmitt K, Holsboer-Trachsler E, Eckert A. BDNF in sleep, insomnia, and sleep deprivation. Ann. Med. 2016; 48: 42–51.
88. Sen S, Duman R, Sanacora G. Serum brain-derived neurotrophic factor, depression, and antidepressant medications: Meta-analyses and implications. Biol. Psychiatry 2008; 64: 527–532.
89. Björkholm C, Monteggia LM. BDNF – a key transducer of antidepressant effects. Neuropharmacology 2016; 102: 72–79.
90. Rybakowski JK. Response to lithium in bipolar disorder: Clinical and genetic findings. ACS Chem. Nerosci. 2014; 5: 413–421.
91. Chepenik LG, Fredericks C, Papademetris X et al. Effects of the brain-derived neurotrophic growth factor val66met variation on hippocampus morphology in bipolar disorder. Neuropsychopharmacology 2009; 34: 944–951.
92. Harrisberger F, Smieskova R, Schmidt A et al. BDNF Val66Met polymorphism and hippocampal volume in neuropsychiatric disorders: A systematic review and meta-analysis. Neurosci. Biobehav. Rev. 2015; 55: 107–118.
93. Wang Z, Li Z, Gao K, Fang Y. Association between brain-derived neurotrophic factor genetic polymorphism Val66Met and susceptibility to bipolar disorder: A meta-analysis. BMC Psychiatry 2014; 14: 366.
94. Chen SL, Lee SY, Chang YH et al. The BDNF Val66Met polymorphism and plasma brain-derived neurotrophic factor levels in Han Chinese patients with bipolar disorder and schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 2014; 51: 99–104.
95. Barbosa IG, Huguet RB, Neves FS et al. Impaired nerve growth factor homeostasis in patients with bipolar disorder. World J. Biol. Psychiatry 2011; 12: 228–232.
96. Kim YK, Na KS, Hwang JA et al. High insulin-like growth factor-1 in patients with bipolar I disorder: A trait marker? J. Affect. Disord. 2013; 151: 738–743.
97. Fernandes BS, Gama CS, Walz JC et al. Increased neurotrophin-3 in drug-free subjects with bipolar disorder during manic and depressive episodes. J. Psychiatr. Res. 2010; 44: 561–565.
98. Walz JC, Magalhães PV, Giglio LM et al. Increased serum neurotrophin-4/5 levels in bipolar disorder. J. Psychiatr. Res. 2009; 43: 721–723.
99. Rybakowski JK, Permoda-Osip A, Skibinska M, Adamski R, Bartkowska-Sniatkowska A. Single ketamine infusion in bipolar depression resistant to antidepressants: Are neurotrophins involved? Hum. Psychopharmacol. 2013; 28: 87–90.
100. Zhang X, Zhang Z, Sha W et al. Effect of treatment on serum glial cell line-derived neurotrophic factor in bipolar patients. J. Affect. Disord. 2010; 126: 326–329.
101. Pereira AC, McQuillin A, Puri V et al. Genetic association and sequencing of the insulin-like growth factor 1 gene in bipolar affective disorder. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2011; 156: 177–187.
102. Palomino A, González-Pinto A, Martinez-Cengotitabengoa M et al. Relationship between negative symptoms and plasma levels of insulin-like growth factor 1 in first-episode schizophrenia and bipolar disorder patients. Prog. Neuropsychopharmacol. Biol. Psychiatry 2013; 44: 29–33.
103. Squassina A, Costa M, Congiu D et al. Insulin-like growth factor 1 (IGF-1) expression is up-regulated in lymphoblastoid cell lines of lithium responsive bipolar disorder patients. Pharmacol. Res. 2013; 73: 1–7.
104. Milanesi E, Hadar A, Maffioletti E et al. Insulin-like growth factor 1 differentially affects lithium sensitivity of lymphoblastoid cell lines from lithium responder and non-responder bipolar disorder patients. J. Mol. Neurosci. 2015; 56: 681–687.
105. Lee BH, Kim YK. Increased plasma VEGF levels in major depressive or manic episodes in patients with mood disorders. J. Affect. Disord. 2012; 136: 181–184.
106. Shibata T, Yamagata H, Uchida S et al. The alteration of hypoxia inducible factor-1 (HIF-1) and its target genes in mood disorder patients. Prog. Neuropsychopharmacol. Biol. Psychiatry 2013; 43: 222–229.
107. Kikuchi K, Iga J, Tayoshi S et al. Lithium decreases VEGF mRNA expression in leukocytes of healthy subjects and patients with bipolar disorder. Hum. Psychopharmacol. 2011; 26: 358–363.
108. Pan W, Banks WA, Kastin AJ. Permeability of the blood–brain barrier to neurotrophins. Brain Res. 1998b; 788: 87–94.
109. Pan W, Kastin AJ, Maness LM, Brennan JM. Saturable entry of ciliary neurotrophic factor into brain. Neurosci. Lett. 1999; 263: 69–71.
110. Pan W, Kastin AJ. Interactions of IGF-1 with the blood–brain barrier in vivo and in situ. Neuroendocrinology 2000; 72: 171–178.
111. Boado RJ, Pardridge WM. Comparison of blood–brain barrier transport of glial-derived neurotrophic factor (GDNF) and an IgG-GDNF fusion protein in the rhesus monkey. Drug Metab. Dispos. 2009; 37: 2299–2304.
112. Zhang ZG, Zhang L, Jiang Q et al. VEGF enhances angiogenesis and promotes blood–brain barrier leakage in the ischemic brain. J. Clin. Invest. 2000; 106: 829–838.
113. Duman RS, Heninger GR, Nestler EJ. A molecular and cellular theory of depression. Arch. Gen. Psychiatry 1997; 54: 597–606.
114. Duman RS. Synaptic plasticity and mood disorders. Mol. Psychiatry 2002; 7 Suppl. 1: S29–S34.
115. Zarate CA, Jr, Singh J, Manji HK. Cellular plasticity cascades: Targets for the development of novel therapeutics for bipolar disorder. Biol. Psychiatry 2006; 59: 1006–1020.
116. Duric V, Duman RS. Depression and treatment response: Dynamic interplay of signaling pathways and altered neural processes. Cell. Mol. Life Sci. 2013; 70: 39–53.
117. Gould TD, Chen G, Manji HK. Mood stabilizer psychopharmacology. Clin. Neurosci. Res. 2002; 2: 193–212.
118. Gould TD, Picchini AM, Einat H, Manji HK. Targeting glycogen synthase kinase-3 in the CNS: Implications for the development of new treatments for mood disorders. Curr. Drug Targets 2006; 7: 1399–1409.
119. Santarelli L, Saxe M, Gross C et al. Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science 2003; 301: 805–809.
120. Sapolsky RM. Is impaired neurogenesis relevant to the affective symptoms of depression? Biol. Psychiatry 2004; 56: 137–139.
121. Gass P, Riva MA. CREB, neurogenesis and depression. Bioessays 2007; 29: 957–961.
122. Pittenger C, Duman RS. Stress, depression, and neuroplasticity: A convergence of mechanisms. Neuropsychopharmacology 2008; 33: 88–109.
123. Castrén E, Rantamäki T. Role of brain-derived neurotrophic factor in the aetiology of depression: Implications for pharmacological treatment. CNS Drugs 2010; 24: 1–7.
124. Hayashi T. Conversion of psychological stress into cellular stress response: Roles of the sigma-1 receptor in the process. Psychiatry Clin. Neurosci. 2015; 69: 179–191.
125. Monji A, Kato T, Kanba S. Cytokines and schizophrenia: Microglia hypothesis of schizophrenia. Psychiatry Clin. Neurosci. 2009; 63: 257–265.
126. Kunugi H, Hori H, Ogawa S. Biochemical markers subtyping major depressive disorder. Psychiatry Clin. Neurosci. 2015; 69: 597–608.
127. Wang TY, Lee SY, Chen SL et al. The differential levels of inflammatory cytokines and BDNF among bipolar spectrum disorders. Int. J. Neuropsychopharmacol. 2016. doi: 10.1093/ijnp/pyw012
128. Eaton WW, Pedersen MG, Nielsen PR, Mortensen PB. Autoimmune diseases, bipolar disorder, and non-affective psychosis. Bipolar Disord. 2010; 12: 638–646.
129. do Prado CH, Rizzo LB, Wieck A et al. Reduced regulatory T cells are associated with higher levels of Th1/TH17 cytokines and activated MAPK in type 1 bipolar disorder. Psychoneuroendocrinology 2013; 38: 667–676.
130. Kato TA, Yamauchi Y, Horikawa H et al. Neurotransmitters, psychotropic drugs and microglia: Clinical implications for psychiatry. Curr. Med. Chem. 2013; 20: 331–344.
131. Frick LR, Williams K, Pittenger C. Microglial dysregulation in psychiatric disease. Clin. Dev. Immunol. 2013; 2013: 608654.
132. Réus GZ, Fries GR, Stertz L et al. The role of inflammation and microglial activation in the pathophysiology of psychiatric disorders. Neuroscience 2015; 300: 141–154.
133. Bezchlibnyk YB, Wang JF, McQueen GM, Young LT. Gene expression differences in bipolar disorder revealed by cDNA array analysis of post-mortem frontal cortex. J. Neurochem. 2001; 79: 826–834.
134. Rao JS, Harry GJ, Rapoport SI, Kim HW. Increased excitotoxicity and neuroinflammatory markers in postmortem frontal cortex from bipolar disorder patients. Mol. Psychiatry 2010; 15: 384–392.
135. Dong XH, Zhen XC. Glial pathology in bipolar disorder: Potential therapeutic implications. CNS Neurosci. Ther. 2015; 21: 393–397.
136. Muneer A. Bipolar disorder: Role of inflammation and the development of disease biomarkers. Psychiatry Invest. 2016; 13: 18–33.
137. Kunz M, Ceresér KM, Goi PD et al. Serum levels of IL-6, IL-10 and TNF-α in patients with bipolar disorder and schizophrenia: Differences in pro- and anti-inflammatory balance. Rev. Bras. Psiquiatr. 2011; 33: 268–274.
138. Barbosa IG, Machado-Vieira R, Soares JC, Teixeira AL. The immunology of bipolar disorder. Neuroimmunomodulation 2014; 21: 117–122.
139. Patel JP, Frey BN. Disruption in the blood–brain barrier: The missing link between brain and body inflammation in bipolar disorder? Neural Plast. 2015; 70: 830–836.
140. Garden GA. Epigenetics and the modulation of neuroinflammation. Neurotherapeutics 2013; 10: 782–788.
141. Andreazza AC, Cassini C, Rosa AR et al. Serum S100B and antioxidant enzymes in bipolar patients. J. Psychiatr. Res. 2007; 41: 523–529.
142. Schroeter ML, Sacher J, Steiner J, Schoenknecht P, Mueller K. Serum S100B represents a new biomarker for mood disorders. Curr. Drug Targets 2013; 14: 1237–1248.
143. Schroeter ML, Steiner J, Schönknecht P, Mueller K. Further evidence for a role of S100B in mood disorders: A human gene expression mega-analysis. J. Psychiatr. Res. 2014; 53: 84–86.
144. Ramesh G, MacLean AG, Philipp MT. Cytokines and chemokines at the crossroads of neuroinflammation, neurodegeneration, and neuropathic pain. Mediators Inflamm. 2013; 480: 73–79.
145. Mika J, Zychowska M, Popiolek-Barczyk K, Rojewska E, Przewlocka B. Importance of glial activation in neuropathic pain. Eur. J. Pharmacol. 2013; 716: 106–119.
146. Hamdani N, Doukhan R, Kurtlucan O, Tamouza R, Leboyer M. Immunity, inflammation, and bipolar disorder: Diagnostic and therapeutic implications. Curr. Psychiatry Rep. 2013; 15: 387.
147. Kim YK, Myint AM, Lee BH et al. T-helper types 1, 2, and 3 cytokine interactions in symptomatic manic patients. Psychiatry Res. 2004; 129: 267–272.
148. Kim YK, Jung HG, Myint AM, Kim H, Park SH. Imbalance between pro-inflammatory and anti-inflammatory cytokines in bipolar disorder. J. Affect. Disord. 2007; 104: 91–95.
149. Brietzke E, Stertz L, Fernandes BS et al. Comparison of cytokine levels in depressed, manic and euthymic patients with bipolar disorder. J. Affect. Disord. 2009; 116: 214–217.
150. Barbosa IG, Huguet RB, Mendonça VA et al. Increased plasma levels of soluble TNF receptor I in patients with bipolar disorder. Eur. Arch. Psychiatry Clin. Neurosci. 2011; 261: 139–143.
151. Kauer-Sant'Anna M, Kapczinski F, Andreazza AC et al. Brain-derived neurotrophic factor and inflammatory markers in patients with early- vs. late-stage bipolar disorder. Int. J. Neuropsychopharmacol. 2009; 12: 447–458.
152. Dickerson F, Stallings C, Origoni A, Boronow J, Yolken R. Elevated serum levels of C-reactive protein are associated with mania symptoms in outpatients with bipolar disorder. Prog. Neuropsychopharmacol. Biol. Psychiatry 2007; 31: 952–955.
153. Dickerson F, Katsafanas E, Schweinfurth LA et al. Immune alterations in acute bipolar depression. Acta Psychiatr. Scand. 2015; 132: 204–210.
154. Hope S, Melle I, Aukrust P et al. Similar immune profile in bipolar disorder and schizophrenia: Selective increase in soluble tumor necrosis factor receptor I and von Willebrand factor. Bipolar Disord. 2009; 11: 726–734.
155. Barbosa IG, Rocha NP, Bauer ME et al. Chemokines in bipolar disorder: Trait or state? Eur. Arch. Psychiatry Clin. Neurosci. 2013; 263: 159–165.
156. Bhattacharya A, Derecki NC, Lovenberg TW, Drevets WC. Role of neuro-immunological factors in the pathophysiology of mood disorders. Psychopharmacology (Berl) 2016; 233: 1623–1636.
157. Modabbernia A, Taslimi S, Brietzke E, Ashrafi M. Cytokine alterations in bipolar disorder: A meta-analysis of 30 studies. Biol. Psychiatry 2013; 74: 15–25.
158. Munkholm K, Braüner JV, Kessing LV, Vinberg M. Cytokines in bipolar disorder vs. healthy control subjects: A systematic review and meta-analysis. J. Psychiatr. Res. 2013; 47: 1119–1133.
159. Goldsmith DR, Rapaport MH, Miller BJ. A meta-analysis of blood cytokine network alterations in psychiatric patients: Comparisons between schizophrenia, bipolar disorder and depression. Mol. Psychiatry 2016; 21: 1696–1709.
160. Daban C, Vieta E, Mackin P, Young AH. Hypothalamic–pituitary–adrenal axis and bipolar disorder. Psychiatr. Clin. North Am. 2005; 28: 469–480.
161. Girshkin L, Matheson SL, Shepherd AM, Green MJ. Morning cortisol levels in schizophrenia and bipolar disorder: A meta-analysis. Psychoneuroendocrinology 2014; 49: 187–206.
162. Belvederi Murri M, Prestia D, Mondelli V et al. The HPA axis in bipolar disorder: Systematic review and meta-analysis. Psychoneuroendocrinology 2016; 63: 327–342.
163. Kunugi H, Hori H, Adachi N, Numakawa T. Interface between hypothalamic–pituitary–adrenal axis and brain-derived neurotrophic factor in depression. Psychiatry Clin. Neurosci. 2010; 64: 447–459.
164. Rybakowski JK, Skibinska M, Leszczynska-Rodziewicz A, Kaczmarek L, Hauser J. Matrix metalloproteinase-9 gene and bipolar mood disorder. Neuromolecular Med. 2009; 11: 128–132.
165. Rybakowski JK, Remlinger-Molenda A, Czech-Kucharska A, Wojcicka M, Michalak M, Losy J. Increased serum matrix metalloproteinase-9 (MMP-9) levels in young patients during bipolar depression. J. Affect. Disord. 2013; 146: 286–289.
166. Haenisch F, Alsaif M, Guest PC et al. Multiplex immunoassay analysis of plasma shows differences in biomarkers related to manic or mixed mood states in bipolar disorder patients. J. Affect. Disord. 2015; 185: 12–16.
167. Beumer W, Gibney SM, Drexhage RC et al. The immune theory of psychiatric diseases: A key role for activated microglia and circulating monocytes. J. Leukoc. Biol. 2012; 92: 959–975.
168. Hoyo-Becerra C, Schlaak JF, Hermann DM. Insights from interferon-α-related depression for the pathogenesis of depression associated with inflammation. Brain Behav. Immun. 2014; 42: 222–231.
169. Pace TW, Miller AH. Cytokines and glucocorticoid receptor signaling. Relevance to major depression. Ann. N. Y. Acad. Sci. 2009; 1179: 86–105.
170. Stokes L, Spencer SJ, Jenkins TA. Understanding the role of P2X7 in affective disorders – are glial cells the major players? Front. Cell. Neurosci. 2015; 9: 258.
171. Maes M, Leonard BE, Myint AM, Kubera M, Verkerk R. The new '5-HT' hypothesis of depression: Cell-mediated immune activation induces indoleamine 2,3-dioxygenase, which leads to lower plasma tryptophan and an increased synthesis of detrimental tryptophan catabolites (TRYCATs), both of which contribute to the onset of depression. Prog. Neuropsychopharmacol. Biol. Psychiatry 2011; 35: 702–721.
172. Myint AM, Kim YK. Network beyond IDO in psychiatric disorders: Revisiting neurodegeneration hypothesis. Prog. Neuropsychopharmacol. Biol. Psychiatry 2014; 48: 304–313.
173. Miller CL, Llenos IC, Dulay JR, Weis S. Upregulation of the initiating step of the kynurenine pathway in postmortem anterior cingulate cortex from individuals with schizophrenia and bipolar disorder. Brain Res. 2006; 1073-1074: 25–37.
174. Miller CL, Llenos IC, Cwik M, Walkup J, Weis S. Alterations in kynurenine precursor and product levels in schizophrenia and bipolar disorder. Neurochem. Int. 2008; 52: 1297–1303.
175. Moylan S, Berk M, Dean OM et al. Oxidative & nitrosative stress in depression: Why so much stress? Neurosci. Biobehav. Rev. 2014; 45: 46–62.
176. Knijff EM, Breunis MN, van Geest MC et al. A relative resistance of T cells to dexamethasone in bipolar disorder. Bipolar Disord. 2006; 8: 740–750.
177. Rensing L, Meyer-Grahle U, Ruoff P. Biological timing and the clock metaphor: Oscillatory and hourglass mechanisms. Chronobiol. Int. 2001; 18: 329–369.
178. Nurnberger JI, Jr, Adkins S, Lahiri DK et al. Melatonin suppression by light in euthymic bipolar and unipolar patients. Arch. Gen. Psychiatry 2000; 57: 572–579.
179. Pohanka M. Impact of melatonin on immunity: A review. Cent. Eur. J. Med. 2013; 8: 369–376.
180. Srinivasan V, Smits M, Spence W et al. Melatonin in mood disorders. World J. Biol. Psychiatry 2006; 7: 138–151.
181. Nováková M, Praško J, Látalová K, Sládek M, Sumová A. The circadian system of patients with bipolar disorder differs in episodes of mania and depression. Bipolar Disord. 2015; 17: 303–314.
182. Seleem MA, Merranko JA, Goldstein TR et al. The longitudinal course of sleep timing and circadian preferences in adults with bipolar disorder. Bipolar Disord. 2015; 17: 392–402.
183. Kripke DF, Elliott JA, Welsh DK, Youngstedt SD. Photoperiodic and circadian bifurcation theories of depression and mania. F1000Res. 2015; 4: 107.
184. Zisapel N. Melatonin-dopamine interactions: From basic neurochemistry to a clinical setting. Cell. Mol. Neurobiol. 2001; 21: 605–616.
185. Landgraf D, McCarthy MJ, Welsh DK. Circadian clock and stress interactions in the molecular biology of psychiatric disorders. Curr. Psychiatry Rep. 2014; 16: 483.
186. Schnell A, Sandrelli F, Ranc V et al. Mice lacking circadian clock components display different mood-related behaviors and do not respond uniformly to chronic lithium treatment. Chronobiol. Int. 2015; 32: 1075–1089.
187. Hampp G, Ripperger JA, Houben T et al. Regulation of monoamine oxidase a by circadian-clock components implies clock influence on mood. Curr. Biol. 2008; 18: 678–683.
188. Kurabayashi N, Hirota T, Sakai M, Sanada K, Fukada Y. DYRK1A and glycogen synthase kinase 3β, a dual-kinase mechanism directing proteasomal degradation of CRY2 for circadian timekeeping. Mol. Cell. Biol. 2010; 30: 1757–1768.
189. Bechtel W. Circadian rhythms and mood disorders: Are the phenomena and mechanisms causally related? Front. Psychiatry 2015; 6: 118.
190. Maes M, Galecki P, Chang YS, Berk M. A review on the oxidative and nitrosative stress (O&NS) pathways in major depression and their possible contribution to the (neuro)degenerative processes in that illness. Prog. Neuropsychopharmacol. Biol. Psychiatry 2011; 35: 676–692.
191. Andreazza AC, Wang JF, Salmasi F, Shao L, Young LT. Specific subcellular changes in oxidative stress in prefrontal cortex from patients with bipolar disorder. J. Neurochem. 2013; 127: 552–561.
192. Versace A, Andreazza AC, Young LT et al. Elevated serum measures of lipid peroxidation and abnormal prefrontal white matter in euthymic bipolar adults: Toward peripheral biomarkers of bipolar disorder. Mol. Psychiatry 2014; 19: 200–208.
193. Brown NC, Andreazza AC, Young LT. An updated meta-analysis of oxidative stress markers in bipolar disorder. Psychiatry Res. 2014; 218: 61–68.
194. Lucas K, Maes M. Role of the toll like receptor (TLR) radical cycle in chronic inflammation: Possible treatments targeting the TLR4 pathway. Mol. Neurobiol. 2013; 48: 190–204.
195. Kapczinski F, Frey BN, Andreazza AC, Kauer-Sant'Anna M, Cunha AB, Post RM. Increased oxidative stress as a mechanism for decreased BDNF levels in acute manic episodes. Rev. Bras. Psiquiatr. 2008; 30: 243–245.
196. Kim HK, Mendonça KM, Howson PA, Brotchie JM, Andreazza AC. The link between mitochondrial complex I and brain-derived neurotrophic factor in SH-SY5Y cells—The potential of JNX1001 as a therapeutic agent. Eur. J. Pharmacol. 2015; 764: 379–384.
197. Fattal O, Budur K, Vaughan AJ, Franco K. Review of the literature on major mental disorders in adult patients with mitochondrial diseases. Psychosomatics 2006; 47: 1–7.
198. Shao L, Martin MV, Watson SJ et al. Mitochondrial involvement in psychiatric disorders. Ann. Med. 2008; 40: 281–295.
199. Jou S-H, Chiu N-Y, Liu C-S. Mitochondrial dysfunction and psychiatric disorders. Chang Gung Med. J. 2009; 32: 370–379.
200. Hroudová J, Singh N, Fišar Z. Mitochondrial dysfunctions in neurodegenerative diseases: Relevance to Alzheimer's disease. Biomed. Res. Int. 2014; 17: 50–62.
201. Streck EL, Gonçalves CL, Furlanetto CB, Scaini G, Dal-Pizzol F, Quevedo J. Mitochondria and the central nervous system: Searching for a pathophysiological basis of psychiatric disorders. Rev. Bras. Psiquiatr. 2014; 36: 156–167.
202. Toker L, Agam G. Mitochondrial dysfunction in psychiatric morbidity: Current evidence and therapeutic prospects. Neuropsychiatr. Dis. Treat. 2015; 11: 2441–2447.
203. Clay HB, Sillivan S, Konradi C. Mitochondrial dysfunction and pathology in bipolar disorder and schizophrenia. Int. J. Dev. Neurosci. 2011; 29: 311–324.
204. de Sousa RT, Machado-Vieira R, Zarate CA, Jr, Manji HK. Targeting mitochondrially mediated plasticity to develop improved therapeutics for bipolar disorder. Expert Opin. Ther. Targets 2014; 18: 1131–1147.
205. Maes M, Yirmyia R, Noraberg J et al. The inflammatory & neurodegenerative (I & ND) hypothesis of depression: Leads for future research and new drug developments in depression. Metab. Brain Dis. 2009; 24: 27–53.
206. Maes M, Fišar Z, Medina M, Scapagnini G, Nowak G, Berk M. New drug targets in depression: Inflammatory, cell-mediated immune, oxidative and nitrosative stress, mitochondrial, antioxidant, and neuroprogressive pathways. And new drug candidates—Nrf2 activators and GSK-3 inhibitors. Inflammopharmacology 2012; 20: 127–150.
207. Kim HK, Chen W, Andreazza AC. The potential role of the NLRP3 inflammasome as a link between mitochondrial complex I dysfunction and inflammation in bipolar disorder. Neural Plast. 2015; 40: 813–816.
208. Stork C, Renshaw PF. Mitochondrial dysfunction in bipolar disorder: Evidence from magnetic resonance spectroscopy research. Mol. Psychiatry 2005; 10: 900–919.
209. Yildiz-Yesiloglu A, Ankerst DP. Neurochemical alterations of the brain in bipolar disorder and their implications for pathophysiology: A systematic review of the in vivo proton magnetic resonance spectroscopy findings. Prog. Neuropsychopharmacol. Biol. Psychiatry 2006; 30: 969–995.
210. Kraguljac NV, Reid M, White D et al. Neurometabolites in schizophrenia and bipolar disorder – a systematic review and meta-analysis. Psychiatry Res. 2012; 203: 111–125.
211. Dodd S, Maes M, Anderson G, Dean OM, Moylan S, Berk M. Putative neuroprotective agents in neuropsychiatric disorders. Prog. Neuropsychopharmacol. Biol. Psychiatry 2013; 42: 135–145.
212. Quiroz JA, Gray NA, Kato T, Manji HK. Mitochondrially mediated plasticity in the pathophysiology and treatment of bipolar disorder. Neuropsychopharmacology 2008; 33: 2551–2565.
213. Hroudová J, Fišar Z. In vitro inhibition of mitochondrial respiratory rate by antidepressants. Toxicol. Lett. 2012; 213: 345–352.
214. Nierenberg AA, Kansky C, Brennan BP, Shelton RC, Perlis R, Iosifescu DV. Mitochondrial modulators for bipolar disorder: A pathophysiologically informed paradigm for new drug development. Aust. N. Z. J. Psychiatry 2013; 47: 26–42.
215. Callaly E, Walder K, Morris G, Maes M, Debnath M, Berk M. Mitochondrial dysfunction in the pathophysiology of bipolar disorder: Effects of pharmacotherapy. Mini Rev. Med. Chem. 2015; 15: 355–365.
216. Kim HK, Nunes PV, Oliveira KC, Young LT, Lafer B. Neuropathological relationship between major depression and dementia: A hypothetical model and review. Prog. Neuropsychopharmacol. Biol. Psychiatry 2016; 67: 51–57.
217. Berridge MJ, Lipp P, Bootman MD. The versatility and universality of calcium signalling. Nat. Rev. Mol. Cell Biol. 2000; 1: 11–21.
218. Nicholls DG. Mitochondrial calcium function and dysfunction in the central nervous system. Biochim. Biophys. Acta 1787; 2009: 1416–1424.
219. 10, resveratrol, acetylcysteine and acetylcarnitine on mitochondrial respiration. Folia Biol. (Praha) 2016; 62: 53–66.
220. Kato T, Kato N. Mitochondrial dysfunction in bipolar disorder. Bipolar Disord. 2000; 2: 180–190.
221. Kato T. Mitochondrial dysfunction as the molecular basis of bipolar disorder: Therapeutic implications. CNS Drugs 2007; 21: 1–11.
222. Kato T. Role of mitochondrial DNA in calcium signalling abnormality in bipolar disorder. Cell Calcium 2008; 44: 92–102.
223. Haase J, Brown E. Integrating the monoamine, neurotrophin and cytokine hypotheses of depression – a central role for the serotonin transporter? Pharmacol. Ther. 2015; 147: 1–11.
224. Geddes JR, Miklowitz DJ. Treatment of bipolar disorder. Lancet 2013; 381: 1672–1682.
225. Data-Franco J, Singh A, Popovic D et al. Beyond the therapeutic shackles of the monoamines: New mechanisms in bipolar disorder biology. Prog. Neuropsychopharmacol. Biol. Psychiatry 2016; 72: 73–86.
226. Cipriani A, Barbui C, Salanti G et al. Comparative efficacy and acceptability of antimanic drugs in acute mania: A multiple-treatments meta-analysis. Lancet 2011; 378: 1306–1315.
227. Taylor DM, Cornelius V, Smith L, Young AH. Comparative efficacy and acceptability of drug treatments for bipolar depression: A multiple-treatments meta-analysis. Acta Psychiatr. Scand. 2014; 130: 452–469.
228. Yildiz A, Nikodem M, Vieta E, Correll CU, Baldessarini RJ. A network meta-analysis on comparative efficacy and all-cause discontinuation of antimanic treatments in acute bipolar mania. Psychol. Med. 2015; 45: 299–317.
229. Grande I, Berk M, Birmaher B, Vieta E. Bipolar disorder. Lancet 2016; 387: 1561–1572.
230. Yildiz A, Vieta E, Leucht S, Baldessarini RJ. Efficacy of antimanic treatments: Meta-analysis of randomized, controlled trials. Neuropsychopharmacology 2011; 36: 375–389.
231. Vieta E, Locklear J, Günther O et al. Treatment options for bipolar depression: A systematic review of randomized, controlled trials. J. Clin. Psychopharmacol. 2010; 30: 579–590.
232. Soeiro-de-Souza MG, Dias VV, Figueira ML et al. Translating neurotrophic and cellular plasticity: From pathophysiology to improved therapeutics for bipolar disorder. Acta Psychiatr. Scand. 2012; 126: 332–341.
233. Miura T, Noma H, Furukawa TA et al. Comparative efficacy and tolerability of pharmacological treatments in the maintenance treatment of bipolar disorder: A systematic review and network meta-analysis. Lancet Psychiatry 2014; 1: 351–359.
234. Khairova R, Pawar R, Salvadore G et al. Effects of lithium on oxidative stress parameters in healthy subjects. Mol. Med. Rep. 2012; 5: 680–682.
235. de Sousa RT, Zarate CA, Jr, Zanetti MV et al. Oxidative stress in early stage bipolar disorder and the association with response to lithium. J. Psychiatr. Res. 2014; 50: 36–41.
236. Magalhães PV, Dean OM, Bush AI et al. N-acetylcysteine for major depressive episodes in bipolar disorder. Rev. Bras. Psiquiatr. 2011; 33: 374–378.
237. Magalhães PV, Dean OM, Bush AI et al. A preliminary investigation on the efficacy of N-acetyl cysteine for mania or hypomania. Aust. N. Z. J. Psychiatry 2013; 47: 564–568.
238. Berk M, Malhi GS, Gray LJ, Dean OM. The promise of N-acetylcysteine in neuropsychiatry. Trends Pharmacol. Sci. 2013; 34: 167–177.
239. Hroudová J, Fišar Z. Connectivity between mitochondrial functions and psychiatric disorders. Psychiatry Clin. Neurosci. 2011; 65: 130–141.
240. Maurer IC, Schippel P, Volz HP. Lithium-induced enhancement of mitochondrial oxidative phosphorylation in human brain tissue. Bipolar Disord. 2009; 11: 515–522.
241. Bachmann RF, Wang Y, Yuan P et al. Common effects of lithium and valproate on mitochondrial functions: Protection against methamphetamine-induced mitochondrial damage. Int. J. Neuropsychopharmacol. 2009; 12: 805–822.
242. Gurvich N, Klein PS. Lithium and valproic acid: Parallels and contrasts in diverse signaling contexts. Pharmacol. Ther. 2002; 96: 45–66.
243. Gould TD, Manji HK. Glycogen synthase kinase-3: A putative molecular target for lithium mimetic drugs. Neuropsychopharmacology 2005; 30: 1223–1237.
244. Quiroz JA, Machado-Vieira R, Zarate CA, Jr, Manji HK. Novel insights into lithium's mechanism of action: Neurotrophic and neuroprotective effects. Neuropsychobiology 2010; 62: 50–60.
245. Rybakowski JK. Factors associated with lithium efficacy in bipolar disorder. Harv. Rev. Psychiatry 2014; 22: 353–357.
246. Dong H, Zhang X, Dai X et al. Lithium ameliorates lipopolysaccharide-induced microglial activation via inhibition of toll-like receptor 4 expression by activating the PI3K/Akt/FoxO1 pathway. J. Neuroinflammation 2014; 11: 140.
247. Chang Y, Lee JJ, Hsieh CY, Hsiao G, Chou DS, Sheu JR. Inhibitory effects of ketamine on lipopolysaccharide-induced microglial activation. Mediators Inflamm. 2009; 2009: 705379.
248. Nery FG, Monkul ES, Hatch JP et al. Celecoxib as an adjunct in the treatment of depressive or mixed episodes of bipolar disorder: A double-blind, randomized, placebo-controlled study. Hum. Psychopharmacol. 2008; 23: 87–94.
249. Berk M, Dean O, Drexhage H et al. Aspirin: A review of its neurobiological properties and therapeutic potential for mental illness. BMC Med. 2013; 11: 74.
250. Savitz J, Preskorn S, Teague TK, Drevets D, Yates W, Drevets W. Minocycline and aspirin in the treatment of bipolar depression: A protocol for a proof-of-concept, randomised, double-blind, placebo-controlled, 2x2 clinical trial. BMJ Open 2012; 2: 643.
251. Rosenblat JD, Kakar R, Berk M et al. Anti-inflammatory agents in the treatment of bipolar depression: A systematic review and meta-analysis. Bipolar Disord. 2016; 18: 89–101.
252. Müller N, Weidinger E, Leitner B, Schwarz MJ. The role of inflammation in schizophrenia. Front. Neurosci. 2015; 9: 372.
253. Kato TA, Monji A, Mizoguchi Y et al. Anti-inflammatory properties of antipsychotics via microglia modulations: Are antipsychotics a 'fire extinguisher' in the brain of schizophrenia? Mini Rev. Med. Chem. 2011; 11: 565–574.
254. Seki Y, Kato TA, Monji A et al. Pretreatment of aripiprazole and minocycline, but not haloperidol, suppresses oligodendrocyte damage from interferon-γ-stimulated microglia in co-culture model. Schizophr. Res. 2013; 151: 20–28.
255. Shao Y, Peng H, Huang Q, Kong J, Xu H. Quetiapine mitigates the neuroinflammation and oligodendrocyte loss in the brain of C57BL/6 mouse following cuprizone exposure for one week. Eur. J. Pharmacol. 2015; 765: 249–257.
256. 2+ signaling as a target of antipsychotic actions for the treatment of schizophrenia. Front. Cell. Neurosci. 2014; 8: 370.
257. Frey BN, Andreazza AC, Houenou J et al. Biomarkers in bipolar disorder: A positional paper from the International Society for Bipolar Disorders Biomarkers Task Force. Aust. N. Z. J. Psychiatry 2013; 47: 321–332.
258. Haenisch F, Alsaif M, Guest PC et al. Multiplex immunoassay analysis of plasma shows prominent upregulation of growth factor activity pathways linked to GSK3β signaling in bipolar patients. J. Affect. Disord. 2014; 156: 139–143.
259. Buoli M, Caldiroli A, Cumerlato Melter C, Serati M, de Nijs J, Altamura AC. Biological aspects and candidate biomarkers for psychotic bipolar disorder: A systematic review. Psychiatry Clin. Neurosci. 2016; 70: 227–244.
260. Duffy A. Toward a comprehensive clinical staging model for bipolar disorder: Integrating the evidence. Can. J. Psychiatry 2014; 59: 659–666.
261. Berk M, Hallam KT, McGorry PD. The potential utility of a staging model as a course specifier: A bipolar disorder perspective. J. Affect. Disord. 2007; 100: 279–281.
262. Kapczinski F, Dias VV, Kauer-Sant'Anna M et al. Clinical implications of a staging model for bipolar disorders. Expert Rev. Neurother. 2009; 9: 957–966.
263. Muneer A. Staging models in bipolar disorder: A systematic review of the literature. Clin. Psychopharmacol. Neurosci. 2016; 14: 117–130.
264. Angst J. Switch from depression to mania, or from mania to depression. J. Psychopharmacol. 1987; 1: 13–19.
265. Leverich GS, Altshuler LL, Frye MA et al. Risk of switch in mood polarity to hypomania or mania in patients with bipolar depression during acute and continuation trials of venlafaxine, sertraline, and bupropion as adjuncts to mood stabilizers. Am. J. Psychiatry 2006; 163: 232–239.
266. Bond DJ, Noronha MM, Kauer-Sant'Anna M, Lam RW, Yatham LN. Antidepressant-associated mood elevations in bipolar II disorder compared with bipolar I disorder and major depressive disorder: A systematic review and meta-analysis. J. Clin. Psychiatry 2008; 69: 1589–1601.
267. Vieta E, Angst J, Reed C, Bertsch J, Haro JM. EMBLEM advisory board. Predictors of switching from mania to depression in a large observational study across Europe (EMBLEM). J. Affect. Disord. 2009; 118: 118–123.
268. Kapczinski F, Vieta E, Andreazza AC et al. Allostatic load in bipolar disorder: Implications for pathophysiology and treatment. Neurosci. Biobehav. Rev. 2008; 32: 675–692.
269. Bizik G, Picard M, Nijjar R et al. Allostatic load as a tool for monitoring physiological dysregulations and comorbidities in patients with severe mental illnesses. Harv. Rev. Psychiatry 2013; 21: 296–313.
270. Grande I, Magalhães PV, Kunz M, Vieta E, Kapczinski F. Mediators of allostasis and systemic toxicity in bipolar disorder. Physiol. Behav. 2012; 106: 46–50.
271. Post RM. Transduction of psychosocial stress into the neurobiology of recurrent affective disorder. Am. J. Psychiatry 1992; 149: 999–1010.
272. Post RM. Kindling and sensitization as models for affective episode recurrence, cyclicity, and tolerance phenomena. Neurosci. Biobehav. Rev. 2007; 31: 858–873.
273. Kendler KS, Thornton LM, Gardner CO. Stressful life events and previous episodes in the etiology of major depression in women: An evaluation of the "kindling" hypothesis. Am. J. Psychiatry 2000; 157: 1243–1251.
274. Bender RE, Alloy LB. Life stress and kindling in bipolar disorder: Review of the evidence and integration with emerging biopsychosocial theories. Clin. Psychol. Rev. 2011; 31: 383–398.
275. Monroe SM, Harkness KL. Life stress, the "kindling" hypothesis, and the recurrence of depression: Considerations from a life stress perspective. Psychol. Rev. 2005; 112: 417–445.
276. Sharma AN, Fries GR, Galvez JF et al. Modeling mania in preclinical settings: A comprehensive review. Prog. Neuropsychopharmacol. Biol. Psychiatry 2016; 66: 22–34.
277. Hasler G, Drevets WC, Gould TD, Gottesman II, Manji HK. Toward constructing an endophenotype strategy for bipolar disorders. Biol. Psychiatry 2006; 60: 93–105.
278. Salvadore G, Quiroz JA, Machado-Vieira R, Henter ID, Manji HK, Zarate CA, Jr. The neurobiology of the switch process in bipolar disorder: A review. J. Clin. Psychiatry 2010; 71: 1488–1501.
279. Chen J, Fang Y, Kemp DE, Calabrese JR, Gao K. Switching to hypomania and mania: Differential neurochemical, neuropsychological, and pharmacologic triggers and their mechanisms. Curr. Psychiatry Rep. 2010; 12: 512–521.
280. Young JW, Dulcis D. Investigating the mechanism(s) underlying switching between states in bipolar disorder. Eur. J. Pharmacol. 2015; 759: 151–162.
281. Murphy DL, Brodie HK, Goodwin FK, Bunney WE, Jr. Regular induction of hypomania by L-dopa in "bipolar" manic-depressive patients. Nature 1971; 229: 135–136.
282. Niitsu T, Fabbri C, Serretti A. Predictors of switch from depression to mania in bipolar disorder. J. Psychiatr. Res. 2015; 66-67: 45–53.
283. Janowsky DS, el-Yousef MK, Davis JM, Sekerke HJ. A cholinergic-adrenergic hypothesis of mania and depression. Lancet 1972; 2: 632–635.
284. van Enkhuizen J, Janowsky DS, Olivier B et al. The catecholaminergic-cholinergic balance hypothesis of bipolar disorder revisited. Eur. J. Pharmacol. 2015; 753: 114–126.
285. Leiva DB. The neurochemistry of mania: A hypothesis of etiology and rationale for treatment. Prog. Neuropsychopharmacol. Biol. Psychiatry 1990; 14: 423–429.
286. Colombo C, Benedetti F, Barbini B, Campori E, Smeraldi E. Rate of switch from depression into mania after therapeutic sleep deprivation in bipolar depression. Psychiatry Res. 1999; 86: 267–270.
287. Payne JL, Quiroz JA, Zarate CA, Jr, Manji HK. Timing is everything: Does the robust upregulation of noradrenergically regulated plasticity genes underlie the rapid antidepressant effects of sleep deprivation? Biol. Psychiatry 2002; 52: 921–926.
288. Lee HJ, Son GH, Geum D. Circadian rhythm hypotheses of mixed features, antidepressant treatment resistance, and manic switching in bipolar disorder. Psychiatry Invest. 2013; 10: 225–232.